Lucid Diagnostics (LUCD) Expected to Announce Earnings on Thursday

Lucid Diagnostics (NASDAQ:LUCD) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Lucid Diagnostics to post earnings of ($0.07) per share and revenue of $1.3880 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:30 AM ET.

Lucid Diagnostics Stock Performance

NASDAQ LUCD opened at $1.34 on Thursday. Lucid Diagnostics has a one year low of $0.95 and a one year high of $1.80. The company has a market capitalization of $184.49 million, a price-to-earnings ratio of -1.29 and a beta of 1.18. The company’s 50-day simple moving average is $1.30 and its two-hundred day simple moving average is $1.18.

Institutional Investors Weigh In On Lucid Diagnostics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new stake in Lucid Diagnostics in the first quarter valued at approximately $39,000. Goldman Sachs Group Inc. increased its position in shares of Lucid Diagnostics by 35.7% during the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after purchasing an additional 22,727 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Lucid Diagnostics by 420.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after purchasing an additional 1,274,194 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after purchasing an additional 32,672 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Lucid Diagnostics in the 2nd quarter worth $97,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Analyst Ratings Changes

LUCD has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Ascendiant Capital Markets upped their target price on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $3.94.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.